Navigation Links
Amarantus BioScience Reports Statistical Significance Achieved for MANF Striatal Reinnervation in Neurorestoration Animal Model of Parkinson's Disease
Date:2/4/2013

SUNNYVALE, Calif., Feb. 4, 2013 /PRNewswire/ -- Amarantus BioScience, Inc. (OTCQB: AMBS), a biotechnology company discovering and developing treatments and diagnostics for diseases associated with neurodegeneration and apoptosis centered around its patented therapeutic protein MANF, today reported that upon further analysis of the data reported on January 9th, 2013, the striatal reinnervation (densitometry) data produced in the 6 hydroxydopamine (6-OHDA) neurorestoration rat model of Parkinson's disease for MANF at 36ug achieved a statistically significant improvement over the data produced for GDNF, with a P value of 0.047.

"The statistical significance uncovered from our in-depth analysis underscores the challenges of evaluating dosing regimens for MANF in standard unilateral rodent models of Parkinson's disease due to MANF's unique ability to reinnervate the striatum," said Dr. John W. Commissiong , Chief Scientist at Amarantus.  "We have been cautious in reporting this first of its kind data thus far, and intend to update the marketplace regarding certain aspects of our further analysis as we move forward. The Company is now preparing to initiate IND-enabling studies." 

The Company has retained a Swiss neuroscience-focused consulting firm to conduct a full audit of the data derived from these experiments and assist the Company in planning for its IND package. The Company will be reporting additional rodent data in the first quarter on a 6-OHDA neuroprotection rat model of Parkinson's disease where both MANF and GDNF were delivered to the substantia nigra. The final report for all rodent experiments will be made public in the second quarter following completion of the
'/>"/>

SOURCE Amarantus BioScience, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Amarantus BioScience Launches New Website
2. Amarantus Bioscience Launches Online Corporate Communication Channels
3. Amarantus Bioscience to Present at OneMedForum 2013
4. Amarantus Appoints Super Bowl Champion Toi Cook to Board of Advisors to Advance TBI Program
5. Amarantus Completes Name Change and CUSIP Change
6. Amarantus BioSciences Announces Positive Data for MANF in Delivery Diffusion Animal Model of Parkinsons Disease
7. Amarantus BioSciences Demands Cessation of Unauthorized Listing on Berlin-Bremen Stock Exchange
8. OneMedPlace Releases Update to Research Report on Amarantus Biosciences Focused on New Positive Ischemic Heart Disease Efficacy Data for MANF in Animals
9. Amarantus BioSciences Wins MANF Patent Challenge in Europe
10. Amarantus BioSciences Issues CEO Letter to Shareholders
11. Amarantus BioSciences Secures $1.1 Million in Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... June 18, 2013 China Cord Blood Corporation ... China,s leading provider of cord blood collection, laboratory testing, ... today announced its preliminary unaudited financial results for the ... ended March 31, 2013. Fourth Quarter ... fourth quarter of fiscal 2013 increased by 33.3% to ...
(Date:6/18/2013)... PA (PRWEB) June 18, 2013 Demanding ... Ball Lenses engineered of synthetic Sapphire and Glass Ball ... sizes from Swiss Jewel Company , of Philadelphia ... by expanding and collimating the light beams without the ... optical clarity and natural durability (9 mohs) make it ...
(Date:6/18/2013)... RegeneCure announced today the start of a ... (GBR) Dental Membrane as a bone stimulating aid for patients ... patients have a tooth replaced with a dental implant is ... Consequently there is often a need to support the implant ... bone substitute material, in turn, needs to be held in ...
(Date:6/18/2013)... , June 18, 2013  AMRI (NASDAQ: ... Burlington, Mass. , site has ... Enforcement Administration (DEA) registration to handle Schedule 2 ... DEA,s acknowledgement of Burlington,s ... and documentation. (Logo: http://photos.prnewswire.com/prnh/20120229/NY61160LOGO ) ...
Breaking Biology Technology:China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 2China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 3China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 4China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 5China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 6China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 7China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 8China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 9China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 10China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 11China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 12China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 13Swiss Jewel Introduces the Crown Jewels of Fiber-Optic Connectors 2RegeneCure Starts Clinical Study Using Polymeric Bone Stimulating Membrane for Dental Implants 2RegeneCure Starts Clinical Study Using Polymeric Bone Stimulating Membrane for Dental Implants 3AMRI Burlington Receives DEA Approval to Handle Controlled Substances 2
... 31 Savient,Pharmaceuticals, Inc. (Nasdaq: SVNT ) today ... and Drug Administration (FDA) seeking approval to,market pegloticase in ... review. Savient,s filing includes data from both the six-month,placebo ... from the Open,Label Extension (OLE) study. The data set ...
... 31 /Xinhua-PRNewswire/ -- Sundia MediTech,Company, a Shanghai-based drug ... this year,s Deloitte Technology,Fast 50 China award, and ... 50 China Program was announced today in Shenzhen, ... 50 Program started in 1995 in San Jose. ...
... than a dozen employers in health care, employment continued to increase in ... like no one was searching for those new jobs. , ... Seattle, ... care field, with an average of 30,000 jobs created each month. Even ...
Cached Biology Technology:Savient Submits Biologics License Application (BLA) for pegloticase 2Savient Submits Biologics License Application (BLA) for pegloticase 3Savient Submits Biologics License Application (BLA) for pegloticase 4Sundia MediTech Ranked #16 in Deloitte Technology Fast 50 China 2The MedZilla Report: September 2008 Employment Outlook for Biotech/Pharma/Health 2The MedZilla Report: September 2008 Employment Outlook for Biotech/Pharma/Health 3
(Date:6/18/2013)... It is estimated that between 5% and 10% of ... is to say that these tumours are attributable to ... BRCA1 or BRCA2. In patients with these mutations, PARP ... encouraging results that make them a new option for ... the latest studies indicate that a fraction of these ...
(Date:6/18/2013)... LA, London (18 June 2013). A team of internationally ... by Dr Sarah Ellis from the University of Lincoln, ... Clinic, Wisconsin, U.S.A. were invited by the International Society ... Feline Practitioners (AAFP) to compile guidelines for veterinarians, owners ... the environmental needs of the domestic cat. The new ...
(Date:6/17/2013)... MA Women in the U.S. exposed to high levels ... likely to have a child with autism as women who ... study from Harvard School of Public Health (HSPH). It is ... and air pollution across the U.S. , "Our findings raise ... the women in our study lived in areas where risk ...
Breaking Biology News(10 mins):An article in 'Cell' reveals a new resistance mechanism to chemotherapy in breast and ovarian cancer 2Feline behavior experts release guidelines to improve the welfare of cats 2Exposure to high pollution levels during pregnancy may increase risk of having child with autism 2
... April 14, 2011 -- The number of couples struggling with ... assisted reproductive technologies, like in vitro fertilization (IVF), to get ... increase the risk of multiple pregnancies (i.e., twins or triplets), ... Twins and triplets are likely to be born prematurely, ...
... 2011 Ceelox, Inc. (OTCBB: CELO) announced today that ... to cloud applications using biometrics. Ceelox ID Online® utilizes ... an Internet server-based biometric software application. This enables users ... credentials, i.e. user name and password, compromised or stolen ...
... The following highlights summarize research papers that have been ... 1. Little Ice Age resulted from more than just ... measure of the amount of light the Sun puts out, ... especially when TSI is notably higher or lower than its ...
Cached Biology News:New study finds stronger regulations of in vitro fertilization may save lives 2Ceelox Provides Biometric Identity Access to Cloud Applications 2Ceelox Provides Biometric Identity Access to Cloud Applications 3AGU journal highlights -- April 13, 2011 2AGU journal highlights -- April 13, 2011 3AGU journal highlights -- April 13, 2011 4AGU journal highlights -- April 13, 2011 5AGU journal highlights -- April 13, 2011 6AGU journal highlights -- April 13, 2011 7
...
BD BioCoat Collagen IV 35 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of mouse collagen type IV....
... are designed for sequencing inserts cloned into ... or T3 RNA polymerase promoters, or lambda ... at a concentration of 0.1 µg/µl in ... DNA sequencing reactions using SequiTherm™ EXCEL™ II ...
BD BioCoat Matrigel Matrix 35 mm Culture Dishes Coating : BD MatrigelTM Basement Membrane Matrix ,Surface : ECM/attachment factors ,Surface area : 9.6 cm2 ,Dim nominal : 35 mm x 10 mm ,Vo...
Biology Products: